Result of Meeting

Argent Biopharma Limited

01 October 2024

 

1 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Results of Shareholder's General Meeting

Argent BioPharma is pleased to announce the voting results from the Company's General Meeting of Shareholders held today, Tuesday, 1 October 2024.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the results can be found in the following URL:

https://www.investi.com.au/api/announcements/rgt/4ae25edd-f7d.pdf

Additionally, the Company advises that it is actively progressing towards the appointment of a sponsor, a key step in moving its listing category from Equity Shares (International Commercial Companies - Secondary Listing) to Equity Shares (Commercial Companies) category (ESCC) of the FCA's Official List. Following the appointment of a sponsor, the Company will be in a position to submit an application to the Financial Conduct Authority (FCA) to facilitate the move between listing categories. Once this process is complete, the Company will provide an updated indicative timetable outlining the anticipated ASX delisting timeline, in accordance with the approval granted by shareholders at the General Meeting held today.

There can be no guarantee whether or when an Application to transfer listing category will be approved, notwithstanding the shareholder approval granted today. The Company will not delist from the ASX without such approval of the Application to transfer to the ESCC.

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

END